Mineralys Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MLYS Nasdaq 2836 mineralystx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Mineralys Therapeutics, Inc.

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Feb 12th, 2025 12:00 pm
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025 - Feb 5th, 2025 9:05 pm
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria - Feb 4th, 2025 1:00 pm
Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials - Jan 9th, 2025 1:29 pm
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension - Jan 8th, 2025 1:00 pm
Mineralys Therapeutics Announces Q3 2024 Results and Updates - Nov 13th, 2024 4:00 am
Q3 2024 Mineralys Therapeutics Inc Earnings Call - Nov 12th, 2024 3:12 pm
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Nov 11th, 2024 9:05 pm
Mineralys Therapeutics to Participate in Upcoming Investor Conferences - Nov 5th, 2024 9:05 pm
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 - Nov 4th, 2024 9:05 pm
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension - Oct 30th, 2024 12:00 pm
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 - Oct 22nd, 2024 12:00 pm
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Oct 20th, 2024 1:10 pm
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension - Sep 25th, 2024 12:00 pm
Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference - Aug 28th, 2024 12:00 pm
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Aug 13th, 2024 8:05 pm
Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 - Aug 5th, 2024 8:05 pm
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares - Jul 12th, 2024 11:01 pm
Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares - Jul 12th, 2024 11:01 pm
Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS) - Jun 21st, 2024 7:11 am